SurvodutideExplore study findings
What the survodutide cardiovascular trial was designed to count
2 numbered sourcesSource years 2023, 2026
Peptides are short chains of amino acids joined by peptide bonds. Some are engineered to activate receptors for more than one hormone. Survodutide is an investigational peptide that activates the glucagon and GLP-1 receptors. The SYNCHRONIZE cardiovascular study was designed to examine whether cardiovascular events occurred at different rates in adults with excess body weight assigned to survodutide or placebo. [1, 2]
The registry describes an event-driven trial. That means the amount of information in the main analysis depends in part on how many specified events occur. The primary combined measure counted the first qualifying event, such as cardiovascular death, nonfatal stroke, nonfatal heart attack, a specified coronary procedure or a heart failure event. Investigators combined these categories because they each provide a way to assess serious cardiovascular outcomes in the studied population. [1]
The stated primary statistical question was noninferiority. Under that design, a prespecified margin defines how much higher the event rate could be while still meeting the criterion. Whether the study met that criterion depends on the observed events and the uncertainty around the estimate. A report of average weight reduction from a separate trial supplies no answer to this question. [1, 2]
The registry update posted on October 29, 2026 listed the study as completed, with no results posted. “Completed” describes the conduct of the study. Event counts and comparative estimates are separate records that have to be reported before readers can assess the outcome. The registry currently supplies the intended test, including the specific events that investigators planned to count. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Boehringer Ingelheim. A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD. ClinicalTrials.gov (publication 2023-10-11, record updated 2026-10-29). (opens in a new tab)
clinicaltrials.gov↩ Back to text
